Literature DB >> 12204795

Estrogen inhibits the initiation of fatty streaks throughout the vasculature but does not inhibit intra-plaque hemorrhage and the progression of established lesions in apolipoprotein E deficient mice.

Michael E Rosenfeld1, Katalin Kauser, Baby Martin-McNulty, Patti Polinsky, Stephen M Schwartz, Gabor M Rubanyi.   

Abstract

Estrogen has previously been shown to inhibit development of early atherosclerotic lesions in hyperlipidemic mice. However, it is still not known whether estrogen also inhibits progression and destabilization of lesions once established and whether there are other effects of long-term hormone therapy in mice. To address this question, male, 20-week old, apolipoprotein E deficient mice were administered 17-beta estradiol or placebo subcutaneously for between 4 and 40 weeks. Estrogen administration did not cause regression of established lesions in the carotid arteries, aortic arch and thoracic aorta but prevented the initiation of new lesions in the abdominal aorta and iliac, femoral and popliteal arteries. Although the established lesions were slightly smaller in the innominate artery of the estrogen treated mice, estrogen did not prevent lesion progression. Estrogen administration also had no effect on the frequency of intra-plaque hemorrhage, atrophy of the fibrous cap, medial erosion, and fibro-fatty nodules, but did reduce the frequency of fatty streaks that form on top of or adjacent to the established lesions in the innominate artery. These data suggest that estrogen inhibits the initiation of the fatty streak but does not alter the progression of established lesions through stages of instability and healing.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12204795     DOI: 10.1016/s0021-9150(02)00178-8

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  24 in total

Review 1.  Estrogen therapies, lipids, and the heart disease prevention controversy.

Authors:  Robert H Knopp; Keiko Aikawa; Eleanor A Knopp
Journal:  Curr Cardiol Rep       Date:  2003-11       Impact factor: 2.931

2.  Effect of hormone therapy and calcitriol on serum lipid profile in postmenopausal older women: association with estrogen receptor-α genotypes.

Authors:  Adarsh J Sai; J Christopher Gallagher; Xiang Fang
Journal:  Menopause       Date:  2011-10       Impact factor: 2.953

3.  Menopause and mitochondria: windows into estrogen effects on Alzheimer's disease risk and therapy.

Authors:  Victor W Henderson; Roberta Diaz Brinton
Journal:  Prog Brain Res       Date:  2010       Impact factor: 2.453

4.  Methods and baseline cardiovascular data from the Early versus Late Intervention Trial with Estradiol testing the menopausal hormone timing hypothesis.

Authors:  Howard N Hodis; Wendy J Mack; Donna Shoupe; Stanley P Azen; Frank Z Stanczyk; Juliana Hwang-Levine; Matthew J Budoff; Victor W Henderson
Journal:  Menopause       Date:  2015-04       Impact factor: 2.953

5.  Differential Effect of Plasma Estradiol on Subclinical Atherosclerosis Progression in Early vs Late Postmenopause.

Authors:  Intira Sriprasert; Howard N Hodis; Roksana Karim; Frank Z Stanczyk; Donna Shoupe; Victor W Henderson; Wendy J Mack
Journal:  J Clin Endocrinol Metab       Date:  2019-02-01       Impact factor: 5.958

6.  Neither antioxidants nor genistein inhibit the progression of established atherosclerotic lesions in older apoE deficient mice.

Authors:  Michelle M Averill; Brian J Bennett; Marcello Rattazzi; Rebecca M Rodmyre; Elizabeth A Kirk; Stephen M Schwartz; Michael E Rosenfeld
Journal:  Atherosclerosis       Date:  2008-07-01       Impact factor: 5.162

Review 7.  Mortality associated with hormone replacement therapy in younger and older women: a meta-analysis.

Authors:  Shelley R Salpeter; Judith M E Walsh; Elizabeth Greyber; Thomas M Ormiston; Edwin E Salpeter
Journal:  J Gen Intern Med       Date:  2004-07       Impact factor: 5.128

Review 8.  The role of electron beam computed tomography for measuring coronary artery atherosclerosis.

Authors:  Theodore Mazzone
Journal:  Curr Diab Rep       Date:  2004-02       Impact factor: 4.810

Review 9.  Progression and disruption of advanced atherosclerotic plaques in murine models.

Authors:  Michael E Rosenfeld; Michelle M Averill; Brian J Bennett; Stephen M Schwartz
Journal:  Curr Drug Targets       Date:  2008-03       Impact factor: 3.465

10.  Effects of the selective estrogen receptor modulator raloxifene on coronary outcomes in the Raloxifene Use for The Heart trial: results of subgroup analyses by age and other factors.

Authors:  Peter Collins; Lori Mosca; Mary Jane Geiger; Deborah Grady; Marcel Kornitzer; Messan G Amewou-Atisso; Mark B Effron; Sherie A Dowsett; Elizabeth Barrett-Connor; Nanette K Wenger
Journal:  Circulation       Date:  2009-02-09       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.